MX2020006482A - Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2). - Google Patents

Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).

Info

Publication number
MX2020006482A
MX2020006482A MX2020006482A MX2020006482A MX2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A
Authority
MX
Mexico
Prior art keywords
epha2
peptide ligands
drug conjugates
ligands specific
bicyclic peptide
Prior art date
Application number
MX2020006482A
Other languages
English (en)
Inventor
Philip Huxley
Liuhong Chen
Silvia Pavan
Rietschoten Katerine Van
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1721259.8A external-priority patent/GB201721259D0/en
Priority claimed from GBGB1804102.0A external-priority patent/GB201804102D0/en
Priority claimed from GBGB1818603.1A external-priority patent/GB201818603D0/en
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2020006482A publication Critical patent/MX2020006482A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a polipéptidos que están unidos covalentemente a andamios moleculares no aromáticos de modo que dos o más bucles de péptidos se sostienen entre los puntos de unión al andamio; en particular, la invención describe péptidos que son aglutinantes de alta afinidad del receptor Eph de tirosina quinasa A2 (EphA2); la invención también incluye conjugados de fármacos que comprenden dichos péptidos, conjugados a uno o más grupos efectores y/o funcionales, a composiciones farmacéuticas que comprenden dichos ligandos de péptidos y conjugados de fármacos y al uso de dichos ligandos de péptidos y conjugados de fármacos para prevenir, suprimir o tratar un enfermedad o trastorno caracterizado por sobreexpresión de EphA2 en tejido enfermo (como un tumor).
MX2020006482A 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2). MX2020006482A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1721259.8A GB201721259D0 (en) 2017-12-19 2017-12-19 Bicyclic peptide ligands specific for EphA2
GBGB1804102.0A GB201804102D0 (en) 2018-03-14 2018-03-14 Bicycle peptide ligands specific for EphA2
GBGB1818603.1A GB201818603D0 (en) 2018-11-14 2018-11-14 Bicyclic peptide ligands specific for epha2
PCT/GB2018/053675 WO2019122860A1 (en) 2017-12-19 2018-12-19 Bicyclic peptide ligands specific for epha2

Publications (1)

Publication Number Publication Date
MX2020006482A true MX2020006482A (es) 2020-12-10

Family

ID=64902125

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006482A MX2020006482A (es) 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
MX2020006474A MX2020006474A (es) 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020006474A MX2020006474A (es) 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).

Country Status (27)

Country Link
US (6) US11484602B2 (es)
EP (4) EP3727461B1 (es)
JP (4) JP7293231B2 (es)
KR (2) KR102791088B1 (es)
CN (4) CN111741771B (es)
AU (3) AU2018387417C9 (es)
BR (2) BR112020012349A2 (es)
CA (2) CA3085253A1 (es)
CY (1) CY1125367T1 (es)
DK (3) DK3727461T3 (es)
ES (3) ES3037964T3 (es)
FI (2) FI4053145T3 (es)
HR (2) HRP20251070T1 (es)
HU (2) HUE073547T2 (es)
IL (3) IL275440B2 (es)
LT (2) LT3727461T (es)
MX (2) MX2020006482A (es)
PH (1) PH12020550929A1 (es)
PL (3) PL3727460T3 (es)
PT (3) PT4053145T (es)
RS (1) RS67248B1 (es)
SA (1) SA520412268B1 (es)
SG (2) SG11202005494QA (es)
SI (2) SI3727460T1 (es)
SM (1) SMT202500312T1 (es)
TW (1) TWI825046B (es)
WO (2) WO2019122863A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
JP7551500B2 (ja) 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
US20220184222A1 (en) * 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021028686A1 (en) * 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
ES3033517T3 (en) * 2019-10-03 2025-08-05 Bicycletx Ltd Heterotandem bicyclic peptide complexes
CN114760988A (zh) * 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
KR20230037502A (ko) * 2020-05-20 2023-03-16 바이사이클티엑스 리미티드 넥틴-4에 특이적인 바이사이클릭 펩티드 리간드 및 이의 용도
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers
KR20230141794A (ko) 2021-01-08 2023-10-10 바이사이클티엑스 리미티드 헤테로탠덤 바이사이클릭 펩티드 복합체
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022250431A1 (ko) 2021-05-25 2022-12-01 주식회사 박셀바이오 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포
US20250121076A1 (en) * 2021-08-17 2025-04-17 Medshine Discovery Inc. Polypeptide drug conjugate having novel structure and application thereof
MX2024003876A (es) 2021-09-29 2024-04-19 Conjustar Zhuhai Biologics Co Ltd Conjugado farmaco-polipeptido triciclico y sus aplicaciones.
AU2022365991A1 (en) * 2021-10-14 2024-05-30 Xizang Haisco Pharmaceutical Co., Ltd. Epha2 bicyclic peptide ligand and conjugate thereof
KR20230140746A (ko) * 2022-03-30 2023-10-10 연세대학교 산학협력단 암전이의 검출용 신규 바이오마커
CN116063379B (zh) * 2022-08-23 2025-05-02 中国药科大学 EphA2靶向多肽及其应用
WO2024184661A1 (en) 2023-03-09 2024-09-12 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
CN121532408A (zh) 2023-06-23 2026-02-13 拜斯科技术开发有限公司 对nk细胞具有特异性的双环肽配体
WO2025191096A1 (en) * 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
CN119874840B (zh) * 2025-03-31 2025-08-08 晶核生物医药科技(上海)有限公司 一种双环肽及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
CA2345376C (en) 1998-09-24 2010-03-16 Advanced Research And Technology Institute, Inc. Water-soluble luminescent quantum dots and bioconjugates thereof
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK3031910T3 (en) 2002-02-21 2017-10-23 Inst Virology MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
EP1852441B1 (en) * 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
DK1844337T3 (da) 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
ES2673822T3 (es) * 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
EP2061519B1 (en) 2006-09-15 2016-03-30 Siemens Medical Solutions USA, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
AU2009211253B2 (en) 2008-02-05 2014-11-06 Bicyclerd Limited Methods and compositions
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
AU2012320407B2 (en) 2011-10-07 2017-04-20 Bicyclerd Limited Modulation of structured polypeptide specificity
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
CN105683211B (zh) 2013-10-28 2020-10-20 拜斯科阿迪有限公司 新型多肽
DK3140653T3 (da) 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
EP3613426A1 (en) 2014-05-21 2020-02-26 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
JP2018521960A (ja) * 2015-04-28 2018-08-09 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 酵素で活性化された第ＸＩＩ因子（ＦＸＩＩａ）の新規阻害剤
US20190298681A1 (en) 2016-03-16 2019-10-03 Merrimack Pharmaceuticals, Inc. Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
AU2017252233A1 (en) 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
US10441663B2 (en) 2016-11-27 2019-10-15 Bicyclerd Limited Methods for treating cancer
JP7387440B2 (ja) 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019060645A1 (en) * 2017-09-20 2019-03-28 Look Dynamics, Inc. PHOTONIC NEURONAL NETWORK SYSTEM
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11572370B2 (en) 2018-01-08 2023-02-07 Biohaven Therapeutics Ltd. CD16A binding agents and uses thereof
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
JP7551500B2 (ja) 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CA3122669A1 (en) 2018-12-13 2020-06-18 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
ES3033517T3 (en) 2019-10-03 2025-08-05 Bicycletx Ltd Heterotandem bicyclic peptide complexes
CN114760988A (zh) 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
KR20230141794A (ko) 2021-01-08 2023-10-10 바이사이클티엑스 리미티드 헤테로탠덤 바이사이클릭 펩티드 복합체
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer

Also Published As

Publication number Publication date
TW201927306A (zh) 2019-07-16
FI4053145T3 (fi) 2024-09-09
CN118598945A (zh) 2024-09-06
AU2018387417A1 (en) 2020-07-30
CN111741771B (zh) 2024-08-06
PH12020550929A1 (en) 2021-05-17
PL3727460T3 (pl) 2022-08-22
EP3727461A1 (en) 2020-10-28
CN111787955A (zh) 2020-10-16
CN111787955B (zh) 2024-06-04
AU2018387417B2 (en) 2023-11-23
US11696956B2 (en) 2023-07-11
CY1125367T1 (el) 2025-05-09
US11484602B2 (en) 2022-11-01
ES2987839T3 (es) 2024-11-18
JP7293231B2 (ja) 2023-06-19
KR20200105839A (ko) 2020-09-09
RS67248B1 (sr) 2025-10-31
PL3727461T3 (pl) 2025-10-27
DK3727461T3 (da) 2025-08-18
JP2023130345A (ja) 2023-09-20
BR112020012246A2 (pt) 2020-11-24
BR112020012349A2 (pt) 2020-11-24
JP7404241B2 (ja) 2023-12-25
EP4582436A2 (en) 2025-07-09
US20240000957A1 (en) 2024-01-04
ES3037964T3 (en) 2025-10-08
EP3727460B1 (en) 2022-04-13
AU2018387418A1 (en) 2020-07-30
PT3727461T (pt) 2025-08-29
JP2021506936A (ja) 2021-02-22
FI3727461T3 (fi) 2025-08-15
LT3727461T (lt) 2025-09-25
IL275440A (en) 2020-08-31
IL275440B2 (en) 2024-03-01
HRP20251070T1 (hr) 2025-11-07
PL4053145T3 (pl) 2024-11-25
SI3727461T1 (sl) 2025-11-28
SG11202005495UA (en) 2020-07-29
CN111741771A (zh) 2020-10-02
KR20200105840A (ko) 2020-09-09
HUE059126T2 (hu) 2022-10-28
IL275437B1 (en) 2025-07-01
HUE073547T2 (hu) 2026-01-28
DK4053145T3 (da) 2024-09-09
US20220289792A1 (en) 2022-09-15
CN118909043A (zh) 2024-11-08
IL321490A (en) 2025-08-01
US20190184025A1 (en) 2019-06-20
IL275440B1 (en) 2023-11-01
IL275437A (en) 2020-08-31
SMT202500312T1 (it) 2025-09-12
US11833211B2 (en) 2023-12-05
PT4053145T (pt) 2024-09-10
HRP20220871T1 (hr) 2022-12-23
SG11202005494QA (en) 2020-07-29
ES2922632T3 (es) 2022-09-19
EP4582436A3 (en) 2025-10-08
CA3086257A1 (en) 2019-06-27
AU2018387417C9 (en) 2024-09-12
SI3727460T1 (sl) 2022-11-30
PT3727460T (pt) 2022-07-14
IL275437B2 (en) 2025-11-01
CA3085253A1 (en) 2019-06-27
WO2019122863A1 (en) 2019-06-27
DK3727460T3 (da) 2022-07-11
EP3727460A1 (en) 2020-10-28
AU2024202618A1 (en) 2024-06-13
EP3727461B1 (en) 2025-07-09
US20260000773A1 (en) 2026-01-01
TWI825046B (zh) 2023-12-11
JP7503689B2 (ja) 2024-06-20
EP4053145A1 (en) 2022-09-07
JP2021506910A (ja) 2021-02-22
MX2020006474A (es) 2020-12-11
WO2019122860A1 (en) 2019-06-27
LT3727460T (lt) 2022-07-25
SA520412268B1 (ar) 2023-11-12
AU2018387418B2 (en) 2024-01-25
US20230144799A1 (en) 2023-05-11
KR102890185B1 (ko) 2025-11-24
EP4053145B1 (en) 2024-06-12
KR102791088B1 (ko) 2025-04-08
JP2024138253A (ja) 2024-10-08
US20240189436A1 (en) 2024-06-13
AU2018387417C1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MX2020006482A (es) Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
MX2020013784A (es) Ligandos de peptidos biciclicos especificos para nectina-4.
CY1124157T1 (el) Προσδετες δικυκλικου πεπτιδιου ειδικοι για μτ1-mmρ
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
MX2021006989A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
CL2024002388A1 (es) Agonistas del receptor gpcr, composiciones farmacéuticas y métodos para uso
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2022004572A (es) Conjugados farmacologicos de ligandos peptidicos biciclicos.
SA520420008B1 (ar) جزيئات ترابطية ببتيدية ثنائية الحلقات متعددة الوحدات
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
AR081042A1 (es) Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g
SG11201807936VA (en) Cell injury inducing therapeutic drug for use in cancer therapy
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
EA202192555A1 (ru) Комбинированная терапия для лечения рака
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
MX387785B (es) Compuestos heteroarilo y su uso como farmacos terapeuticos.
AR120440A1 (es) Agonistas del receptor npy2
MX393281B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
AR092736A1 (es) Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
AR113966A1 (es) LIGANDOS PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EphA2
EA202091375A1 (ru) БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, ОБЛАДАЮЩИЕ СПЕЦИФИЧНОСТЬЮ К EphA2
AR115601A1 (es) Ligandos peptídicos bicíclicos específicos para nectina-4